Two Sigma Advisers LP Sells 38,600 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Two Sigma Advisers LP cut its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 10.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 343,600 shares of the company's stock after selling 38,600 shares during the period. Two Sigma Advisers LP owned approximately 0.64% of Fulcrum Therapeutics worth $1,615,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Bank of New York Mellon Corp boosted its position in shares of Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock valued at $667,000 after buying an additional 3,126 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock valued at $567,000 after buying an additional 6,770 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Fulcrum Therapeutics during the fourth quarter valued at $38,000. Wells Fargo & Company MN boosted its position in shares of Fulcrum Therapeutics by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock valued at $161,000 after buying an additional 8,761 shares during the last quarter. Finally, Shay Capital LLC boosted its position in shares of Fulcrum Therapeutics by 4.2% during the fourth quarter. Shay Capital LLC now owns 301,464 shares of the company's stock valued at $1,417,000 after buying an additional 12,227 shares during the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC traded up $0.07 during trading on Tuesday, hitting $7.03. The company had a trading volume of 430,854 shares, compared to its average volume of 969,840. The stock has a 50 day simple moving average of $4.55 and a 200 day simple moving average of $4.07. Fulcrum Therapeutics, Inc. has a 12 month low of $2.32 and a 12 month high of $10.13. The firm has a market capitalization of $379.47 million, a P/E ratio of -22.68 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. As a group, analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on FULC. Cantor Fitzgerald raised Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective on the stock in a research report on Thursday, May 15th. HC Wainwright reissued a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Piper Sandler reissued an "overweight" rating and issued a $9.00 target price (up from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Leerink Partnrs raised Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. Finally, Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Fulcrum Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $6.29.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.